重组人干扰素α-1b雾化治疗小儿毛细支气管炎的疗效观察

Therapeutic effect of recombinant human interferon α-1b on children with bronchiolitis

目的探索重组人干扰素α-1b雾化治疗小儿毛细支气管炎的临床效果。方法选择我院就诊的小儿毛细支气管炎患儿作为探究对象(例数:100例;时间:2017.10.22~2018.7.23),实施信封随机分组模式进行分组,50例/组,分别给予病毒唑、重组人干扰素α-1b雾化治疗,比较两组临床症状消失时间、肺功能指标情况、住院时间、不良反应发生情况。结果观察组临床症状消失时间短于对照组,肺功能指标改善情况优于对照组,住院时间短于对照组,P <0.05,在不良反应发生情况对比中,两组数据无较大差异性,P>0.05。结论重组人干扰素α-1b雾化治疗小儿毛细支气管炎效果较佳,可应用。

Objective To explore the clinical effect of recombinant human interferon α-1 b in the treatment of children with bronchiolitis. Methods The children with bronchiolitis in our hospital were selected as the target of investigation(number of cases: 100 cases;time:2017.10.22~2018.7.23).Envelope random grouping mode was used to group, 50 cases/group, respectively,given ribavirin,Recombinant human interferon α-1 b was used for aerosol therapy,and the disappearance time of clinical symptoms,lung function index,hospitalization time,and adverse reactions were compared between the two groups.Results The disappearance of clinical symptoms in the observation group was shorter than that in the control group.The improvement of lung function index was better than that of the control group.The hospitalization time was shorter than that of the control group,P<0.05.In the comparison of adverse reactions, there was no significant difference between the two groups,P >0.05.Conclusion Recombinant human interferon α-1 b is effective in the treatment of children with bronchiolitis and can be applied.